Clinical Trial

Phase I Study of [111In]-FPI-2107 in EGFR Mutation-positive NSCLC

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated June 17, 2026 (before its estimated July 21, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a Phase I, multicentre, open-label clinical study designed to investigate the safety, tolerability, dosimetry, biodistribution, PD, and PK of \[111In\]-FPI-2107 after pre-dose administration of FPI-2053 in Chinese participants with EGFR mutation-positive NSCLC.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2026-03-25; most recent amendment 2026-06-16.
Trial Details
NCT Number NCT07500987
Lead Sponsor AstraZeneca
Conditions EGFR Mutation-positive NSCLC
Enrollment 12 participants
Start Date 2026-02-27
Primary Completion 2026-07-21 (estimated)
Study Completion 2026-07-21 (estimated)
Updated on ClinicalTrials.gov 2026-06-17